Louvain-la-Neuve, Belgium, April 18, 2019, 17.35

Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on April 16, 2019.

In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and equivalent financial instruments, its total holding in IBA SA has increased and its holding in equivalent financial instruments has crossed upwards the 3 % threshold on April 15, 2019.

In details, on April 15, 2019, Norges Bank owned (A) 106 079 IBA shares with voting rights (versus 74 561 shares in its previous notification), representing 0,35% of the total number of shares issued by IBA (30 122 528) (versus 0,25% in its previous notification), as well as (B) 920 935 equivalent financial instruments (versus 849 428 in its previous notification) representing 3,06% of the total number of shares issued by IBA (30 122 528) (versus 2,82% in its previous notification).

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights
  • Persons subject to the notification requirement: Norges Bank
  • Date on which the threshold is crossed: 15/04/2019
  • Threshold crossed (in %): 3%
  • Denominator: 30 122 528
  • Notified details: (extract of the received notification form), the details can be found in the full press release in the pdf which can be read in the right column
  • Full chain of controlled undertakings through which the holding is effectively held: Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:


Stéphanie Bauwin, Legal Counsel, legal@iba-group.com or +32 10 203 924

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com